Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.

The vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis. However, clinical trials targeting the VEGF pathway are often ineffective, suggesting that other factors/pathways are also important in tumor angiogenesis. We have previously shown that the Notch ligand Delta-like 4 (DLL4) is up-regulated in tumor vasculature. Here, we show that DLL4, when expressed in tumor cells, functions as a negative regulator of tumor angiogenesis by reducing the number of blood vessels in all five types of xenografts, but acts as a positive driver for tumor growth in two of them (human glioblastoma and prostate cancer). The growth of in vivo models was not related to the effects on growth in vitro. DLL4 expressed in the tumor cells activated Notch signaling in host stromal/endothelial cells, increased blood vessel size, and improved vascular function within tumors. The promotion of tumor growth was, to some extent, due to a reduction of tumor hypoxia and apoptosis. DLL4-expressing tumor cells responded to anti-VEGF therapy with bevacizumab. A soluble form of DLL4 (D4ECD-Fc) blocked tumor growth in both bevacizumab-sensitive and bevacizumab-resistant tumors by disrupting vascular function despite increased tumor vessel density. In addition, we show that DLL4 is up-regulated in tumor cells and tumor endothelial cells of human glioblastoma. Our findings provide a rational basis for the development of novel antiangiogenic strategies via blockade of DLL4/Notch signaling and suggest that combined approaches for interrupting both DLL4 and VEGF pathways may improve antiangiogenic therapy.

[1]  Larry Kedes,et al.  HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.

[2]  Yan Li,et al.  Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis , 2003, Molecular and Cellular Biology.

[3]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[4]  Jennifer J. Hofmann,et al.  Notch expression patterns in the retina: An eye on receptor-ligand distribution during angiogenesis. , 2007, Gene expression patterns : GEP.

[5]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[6]  Adrian L Harris,et al.  Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. , 2005, Cancer research.

[7]  F. Speleman,et al.  Gene-expression profiling reveals distinct expression patterns for Classic versus Variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma , 2004, Oncogene.

[8]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[9]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[10]  Colin C. Collins,et al.  Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1 , 1997, Nature Genetics.

[11]  Markus Bredel,et al.  Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes , 2003, Brain pathology.

[12]  A. Harris,et al.  Notch signaling from tumor cells: a new mechanism of angiogenesis. , 2005, Cancer cell.

[13]  S. Artavanis-Tsakonas,et al.  Secreted forms of DELTA and SERRATE define antagonists of Notch signaling in Drosophila. , 1997, Development.

[14]  H. Lassmann,et al.  In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain , 2004, Acta Neuropathologica.

[15]  L. Akslen,et al.  Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.

[16]  J. Rossant,et al.  Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[18]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[19]  M. Fishman,et al.  Gridlock signalling pathway fashions the first embryonic artery , 2001, Nature.

[20]  J. Weissenbach,et al.  Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia , 1996, Nature.

[21]  J. Hsieh,et al.  A secreted Delta1‐Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling , 2002, Journal of neuroscience research.

[22]  Olav Haraldseth,et al.  NG2 proteoglycan promotes angiogenesis‐dependent tumor growth in the central nervous system by sequestering angiostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[24]  Tasuku Honjo,et al.  Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. , 2004, Genes & development.

[25]  Janet Rossant,et al.  Dosage-sensitive requirement for mouse Dll4 in artery development. , 2004, Genes & development.

[26]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[27]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. , 2006, Nature.

[28]  Weidong Jiang,et al.  Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. , 2007, Blood.

[29]  L. Kedes,et al.  Notch Signaling in Vascular Development , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[30]  R. J. Fleming,et al.  A dominant-negative form of Serrate acts as a general antagonist of Notch activation. , 1997, Development.

[31]  Cun-Yu Wang,et al.  Notch signaling in the regulation of tumor angiogenesis. , 2006, Trends in cell biology.

[32]  T. Giordano,et al.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. , 2005, Cancer cell.

[33]  Gavin Thurston,et al.  Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Harris,et al.  Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer , 2006, Clinical Cancer Research.

[35]  R Bicknell,et al.  Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.

[36]  J. Campos-Ortega,et al.  Notch signaling is required for arterial-venous differentiation during embryonic vascular development. , 2001, Development.

[37]  W. Stallcup,et al.  Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. , 1995, Experimental cell research.

[38]  M. Kurabayashi,et al.  Dll4-selective Notch signaling induces ephrinB2 gene expression in endothelial cells. , 2006, Biochemical and biophysical research communications.

[39]  W. Richards,et al.  Dll4, a novel Notch ligand expressed in arterial endothelium. , 2000, Genes & development.

[40]  A. Harris,et al.  Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. , 2006, Blood.

[41]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[42]  Paul S. Meltzer,et al.  Mutations in the human Jagged1 gene are responsible for Alagille syndrome , 1997, Nature Genetics.